Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial
- 1 June 2000
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 139 (6) , 927-933
- https://doi.org/10.1067/mhj.2000.105107
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of strokeJournal of the Neurological Sciences, 1996
- Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular MedicineNew England Journal of Medicine, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- Characterization of a functional thrombin receptor. Issues and opportunities.Journal of Clinical Investigation, 1992
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Platelets and Thrombolytic TherapyNew England Journal of Medicine, 1990